Charles River Laboratories EBITDA Margin 2010-2025 | CRL

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Charles River Laboratories (CRL) over the last 10 years. The current EBITDA margin for Charles River Laboratories as of March 31, 2025 is .
Charles River Laboratories EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2025-03-31 $4.02B $0.79B 19.59%
2024-12-31 $4.05B $0.80B 19.85%
2024-09-30 $4.06B $0.87B 21.37%
2024-06-30 $4.08B $0.89B 21.87%
2024-03-31 $4.11B $0.90B 21.81%
2023-12-31 $4.13B $0.93B 22.55%
2023-09-30 $4.22B $0.96B 22.75%
2023-06-30 $4.18B $0.96B 22.86%
2023-03-31 $4.09B $0.98B 23.86%
2022-12-31 $3.98B $0.96B 24.02%
2022-09-30 $3.78B $0.95B 25.23%
2022-06-30 $3.69B $0.95B 25.81%
2022-03-31 $3.63B $0.89B 24.63%
2021-12-31 $3.54B $0.86B 24.15%
2021-09-30 $3.43B $0.81B 23.49%
2021-06-30 $3.27B $0.77B 23.61%
2021-03-31 $3.04B $0.70B 23.04%
2020-12-31 $2.92B $0.67B 22.85%
2020-09-30 $2.82B $0.64B 22.63%
2020-06-30 $2.75B $0.59B 21.54%
2020-03-31 $2.72B $0.59B 21.55%
2019-12-31 $2.62B $0.55B 20.98%
2019-09-30 $2.53B $0.53B 21.04%
2019-06-30 $2.45B $0.52B 21.06%
2019-03-31 $2.38B $0.51B 21.33%
2018-12-31 $2.27B $0.49B 21.76%
2018-09-30 $2.14B $0.45B 20.77%
2018-06-30 $2.02B $0.43B 21.03%
2018-03-31 $1.91B $0.42B 21.94%
2017-12-31 $1.86B $0.42B 22.56%
2017-09-30 $1.85B $0.43B 23.19%
2017-06-30 $1.81B $0.41B 22.84%
2017-03-31 $1.77B $0.39B 22.00%
2016-12-31 $1.68B $0.36B 21.64%
2016-09-30 $1.57B $0.34B 21.35%
2016-06-30 $1.49B $0.32B 21.58%
2016-03-31 $1.40B $0.31B 22.32%
2015-12-31 $1.36B $0.30B 22.16%
2015-09-30 $1.34B $0.29B 21.88%
2015-06-30 $1.32B $0.29B 21.70%
2015-03-31 $1.32B $0.28B 21.38%
2014-12-31 $1.30B $0.28B 21.26%
2014-09-30 $1.26B $0.26B 20.92%
2014-06-30 $1.22B $0.26B 21.13%
2014-03-31 $1.17B $0.25B 21.31%
2013-12-31 $1.17B $0.26B 22.06%
2013-09-30 $1.16B $0.26B 22.75%
2013-06-30 $1.14B $0.26B 22.57%
2013-03-31 $1.14B $0.26B 23.26%
2012-12-31 $1.13B $0.27B 23.45%
2012-09-30 $1.14B $0.27B 23.84%
2012-06-30 $1.14B $0.27B 24.04%
2012-03-31 $1.14B $0.28B 24.50%
2011-12-31 $1.14B $0.28B 24.50%
2011-09-30 $1.13B $0.18B 15.96%
2011-06-30 $1.13B $0.16B 13.75%
2011-03-31 $1.13B $0.14B 11.97%
2010-12-31 $1.13B $0.12B 10.67%
2010-09-30 $1.12B $0.22B 19.89%
2010-06-30 $1.14B $0.25B 22.07%
2010-03-31 $1.16B $0.27B 22.91%
2009-12-31 $1.17B $0.27B 23.40%
Sector Industry Market Cap Revenue
Medical Medical Services $7.242B $4.050B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $140.550B 26.36
Elevance Health (ELV) United States $84.617B 10.92
CVS Health (CVS) United States $84.212B 10.47
Cencora (COR) United States $56.918B 19.80
Natera (NTRA) United States $23.467B 0.00
DiDi Global (DIDIY) China $22.356B 23.75
Labcorp Holdings (LH) United States $21.919B 17.78
BioMerieux (BMXMF) France $16.861B 0.00
EUROFINS SCIENT (ERFSF) Luxembourg $13.557B 0.00
Solventum (SOLV) United States $12.729B 13.47
CochLear (CHEOY) Australia $12.142B 0.00
ICON (ICLR) Ireland $11.829B 11.00
Revvity (RVTY) United States $11.196B 19.27
Viatris (VTRS) United States $10.411B 3.58
Avantor (AVTR) United States $9.247B 13.44
Medpace Holdings (MEDP) United States $8.892B 23.61
HealthEquity (HQY) United States $8.760B 38.37
Sonic Healthcare (SKHHY) Australia $8.172B 0.00
Amplifon S.p.A (AMFPF) Italy $5.378B 29.44
Bausch + Lomb (BLCO) Canada $4.149B 24.44
BrightSpring Health Services (BTSG) United States $3.915B 35.92
Sotera Health (SHC) United States $3.233B 18.37
Alignment Healthcare (ALHC) United States $2.762B 0.00
Concentras Parent (CON) United States $2.658B 15.36
Organon (OGN) United States $2.535B 2.69
Surgery Partners (SGRY) United States $2.473B 32.17
PACS (PACS) United States $2.009B 0.00
GeneDx Holdings (WGS) United States $1.912B 73.63
Ardent Health (ARDT) United States $1.865B 7.95
Premier (PINC) United States $1.816B 13.79
Progyny (PGNY) United States $1.798B 39.58
GoodRx Holdings (GDRX) United States $1.643B 32.86
Teladoc Health (TDOC) United States $1.211B 0.00
Pediatrix Medical (MD) United States $1.136B 8.64
Establishment Labs Holdings (ESTA) $1.093B 0.00
CareDx (CDNA) United States $1.060B 16.56
Ryman Healthcare (RYHTY) New Zealand $0.999B 0.00
Agilon Health (AGL) United States $0.873B 0.00
AMN Healthcare Services Inc (AMN) United States $0.839B 7.85
QDM (QDMI) Hong Kong, SAR China $0.729B 0.00
LifeMD (LFMD) United States $0.671B 0.00
Nutex Health (NUTX) United States $0.633B 9.58
Embecta (EMBC) United States $0.571B 3.85
InnovAge Holding (INNV) United States $0.525B 0.00
Enhabit (EHAB) United States $0.469B 38.62
Auna S.A (AUNA) Luxembourg $0.460B 10.35
Sonida Senior Living (SNDA) United States $0.452B 0.00
SBC Medicals (SBC) United States $0.447B 0.00
COMPASS Pathways (CMPS) United Kingdom $0.433B 0.00
Omada Health (OMDA) $0.391B 0.00
Performant Healthcare (PHLT) United States $0.269B 0.00
Oncology Institute (TOI) United States $0.213B 0.00
Beauty Health (SKIN) United States $0.203B 0.00
DocGo (DCGO) United States $0.162B 26.50
Pheton Holdings (PTHL) China $0.128B 0.00
OncoCyte (IMDX) United States $0.121B 0.00
So-Young (SY) China $0.119B 0.00
KindlyMD (NAKA) United States $0.086B 0.00
Sera Prognostics (SERA) United States $0.072B 0.00
NeueHealth (NEUE) United States $0.061B 0.00
Ascend Wellness Holdings (AAWH) United States $0.059B 0.00
IceCure Medical (ICCM) Israel $0.053B 0.00
ModivCare (MODV) United States $0.047B 0.00
Basel Medical Group (BMGL) Singapore $0.045B 0.00
Biodesix (BDSX) United States $0.038B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.033B 0.00
Intelligent Bio Solutions (INBS) United States $0.012B 0.00
Co-Diagnostics (CODX) United States $0.009B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
XWELL (XWEL) United States $0.005B 0.00
Aclarion (ACON) United States $0.004B 0.00
SeaStar Medical Holding (ICU) United States $0.004B 0.00
INVO Fertility (IVF) United States $0.003B 0.00
ISpecimen (ISPC) United States $0.002B 0.00
NewGenIvf Group (NIVF) Thailand $0.001B 0.00
Cano Health (CANOQ) United States $0.000B 0.00